Sugi Predict

Sugi Predict / Compounds / SCHEMBL2858799

SCHEMBL2858799

SCHEMBL2858799

N#CCNC(=O)CNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 20/20 0.89
▸ JAK3 P52333 16/20 0.89
▸ JAK1 P23458 10/20 0.89
▸ HDAC1 Q13547 3/20 0.89
▸ TYK2 P29597 2/20 0.89
▸ BMPR1B O00238 1/20 0.89
▸ PLK4 O00444 1/20 0.89
▸ CIT O14578 1/20 0.89
▸ GAK O14976 1/20 0.89
▸ OPA1 O60313 1/20 0.89
▸ ROCK2 O75116 1/20 0.89
▸ STK16 O75716 1/20 0.89
▸ PRKD3 O94806 1/20 0.89
▸ CSNK2A2 P19784 1/20 0.89
▸ CDK2 P24941 1/20 0.89
▸ MARK3 P27448 1/20 0.89
▸ BMPR1A P36894 1/20 0.89
▸ TGFBR1 P36897 1/20 0.89
▸ STAT3 P40763 1/20 0.89
▸ STAT5A P42229 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Momelotinib SCHEMBL22282523 0.94 JAK2 (1.00) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL29352115 0.94 JAK2 (1.00) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL2237234 0.94 JAK2 (1.00) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL17333087 0.93 JAK2 (0.98) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL29774318 0.93 JAK2 (0.98) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL2863022 0.93 JAK2 (0.98) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL2863013 0.93 JAK2 (0.98) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL3619656 0.91 JAK2 (0.93) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL30051896 0.91 JAK2 (0.93) JAK2JAK3JAK1HDAC1TYK2
Momelotinib SCHEMBL3619662 0.91 JAK2 (0.93) JAK2JAK3JAK1HDAC1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof SIERRA ONCOLOGY, INC. (US) 2022-12-08 — — US claimed
EP-3023422-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF YM BioSciences Australia Pty Ltd (AU) 2016-05-25 — — EP claimed
US-9233934-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (US) 2016-01-12 — — US claimed
EP-2152701-B1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF YM BIOSCIENCES AUSTRALIA PTY (AU) 2015-11-11 — — EP claimed
US-20140011803-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2014-01-09 — — US claimed
US-20140005180-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2014-01-02 — — US claimed
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2010-08-05 — — US claimed
EP-2152701-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF Cytopia Research Pty Ltd (AU) 2010-02-17 — — EP claimed
WO-2008109943-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF CYTOPIA RESEARCH PTY LTD (AU) 2008-09-18 — — WO claimed
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof GLAXOSMITH KLINE LLC (US) 2026-03-10 — — US disclosed
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof SIERRA ONCOLOGY, INC. (US) 2022-12-08 — — US disclosed
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof SIERRA ONCOLOGY, INC. (US) 2022-12-08 — — US disclosed
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2021-10-07 — — US disclosed
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2021-10-07 — — US disclosed
US-20140005180-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2014-01-02 — — US disclosed
US-8486941-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-07-16 — — US disclosed
US-8486941-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-07-16 — — US disclosed
US-8486941-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-07-16 — — US disclosed
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2010-08-05 — — US disclosed
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2010-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885JAK1 1/4885
US-20140011803-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885
US-20140005180-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 JAK2 1/4885JAK3 3/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.